Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The patients with acute myocardial infarction (AMI) present high mortality and morbidity
rate,even treated with stenting in the blocked heart vessels.
The appearance of no-reflow is common after re-opening of the blocked vessel. The no-reflow
were commonly attributed to tiny blockage in coronary micro-vasculature by thrombus and spasm
of the micro-vessel during stenting.
An agent with more effective anti-clotting and micro-vessel dilation would be helpful to
solve the issue of no-reflow. Ticagrelor was demonstrated to be a potent platelet inhibitor
and a potent micro-vessel dilator which can influence metabolism of adenosine, a endogenous
potent small vessel dilator.
This study is to test the effectiveness of ticagrelor on improving reperfusion and minimizing
the myocardial infarct size after PPCI in patients with AMI.